# MSD HH Vietnam Context

## Company Overview

**Headquarters Location**: Hanoi or Ho Chi Minh City (verify exact address)

**Market Entry**: MSD (Merck Sharp & Dohme) entered Vietnam in the early 1990s as part of its Southeast Asia expansion.

**Employee Structure**: Approximately 200–300 staff across commercial, medical, regulatory, and manufacturing functions.

**Therapeutic Focus**:
- Vaccines
- Oncology
- Infectious diseases
- Cardiometabolic
- Women's health

## Current Portfolio

**Key Products**:
- Keytruda (oncology)
- Gardasil (HPV vaccine)
- Januvia (diabetes)
- Zepatier (hepatitis C)

**Market Position**: Tier-1 multinational, leader in vaccines and oncology segments

**Market Share**: Estimated ~5–7% of total innovative pharma market (based on IQVIA estimates)

## Strategic Priorities

**Global Southeast Asia Strategy**:
- Focus on access, affordability, and localization of clinical trials

**Vietnam Objectives**:
- Expand vaccination coverage
- Deepen oncology presence
- Build partnerships with hospitals

**Growth Targets**:
- Double-digit CAGR through 2027 (aligned with SEA region benchmarks)

**Expansion Areas**:
- Oncology
- Vaccines
- Diabetes management
- Women's health

## Market Challenges

**Barriers to Growth**:
- Pricing pressure
- Slow regulatory approvals
- Fragmented distribution

**Regulatory Issues**:
- Long drug registration timelines
- Inconsistent pricing policies

**Competition**:
- Intense rivalry from Pfizer, GSK, Novartis, Sanofi, and domestic generics
